MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ
2.790
-0.010
-0.36%
After Hours: 2.860 +0.07 +2.51% 18:48 03/01 EST
OPEN
2.780
PREV CLOSE
2.800
HIGH
2.810
LOW
2.740
VOLUME
916.90K
TURNOVER
0
52 WEEK HIGH
3.145
52 WEEK LOW
1.690
MARKET CAP
467.87M
P/E (TTM)
-6.0000
1D
5D
1M
3M
1Y
5Y
Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target
Benzinga · 2d ago
Buy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospects
TipRanks · 3d ago
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 3d ago
Arbutus Biopharma Anticipates Key 2024 Milestones
TipRanks · 3d ago
Arbutus Biopharma GAAP EPS of -$0.44 beats by $0.01, revenue of $18.1M misses by $3.04M
Seeking Alpha · 3d ago
Arbutus Biopharma Q4 EPS $(0.12), Inline, Sales $2.15M Miss $4.79M Estimate
Arbutus Biopharma reported quarterly losses of $0.12 per share. The company reported quarterly sales of $2.15 million which missed the analyst consensus estimate of $4.79 million. Arbutus also reported a 14.29 percent increase in sales from the same period last year.
Benzinga · 3d ago
Arbutus Biopharma Q4 2023 Earnings Preview
Arbutus Biopharma (NASDAQ:ABUS) is scheduled to announce Q4 earnings results on Thursday, February 29th. The consensus EPS Estimate is -$0.12 and the consensus revenue estimate is $4.86M. Over the last 3 months, EPS estimates have seen 2 upward revisions.
Seeking Alpha · 4d ago
Notable earnings before Thursday's open
Seeking Alpha · 4d ago
More
About ABUS
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, an oral capsid inhibitor, an oral programmed death-ligand-1 (PD-L1) inhibitor, and an oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The Company is also having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses, including SARS-CoV-2.

Webull offers Arbutus Biopharma Corp stock information, including NASDAQ: ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.